December 2012 | OncologyLive

Dual Pathways Must Be Targeted in ER-Positive Breast Cancer

January 04, 2013

Treating estrogen receptor–positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

Ponatinib Could Herald "Revolution" in CML Treatment

December 24, 2012

For the past six years, researchers have been working to develop a treatment for patients with CML who have become resistant to the groundbreaking drug imatinib and to the TKIs dasatinib and nilotinib that were developed subsequently.

A Nobel Prize in Waiting: Understanding Unexpected and Prolonged Remissions

December 19, 2012

Ipilimumab provides a striking example of the way in which some patients derive long-term benefits from therapy while others do not. The reasons for such differences should be a priority for translational research.